The role of PI3-K/Akt signal pathway in the antagonist effect of CEPO on CHF rats

Abstract

The possible role of phosphoinositide 3-kinase (PI3-K)/protein kinase B (Akt) signal pathway in the antagonist effect of carbamylated erythropoietin (CEPO) on chronic heart failure (CHF) in rats was investigated. Twenty of 120 rats were randomly selected as the control group, and the remaining rats as the model group. Rats in the model group received intraperitoneal injection of isoproterenol, those in the control group underwent intraperitoneal injection of equivalent normal saline. Rats with successful model establishment were divided into 4 groups, i.e. CHF group, CEPO group, LY294002 (LY) group and CEPO + LY group. Rats in the CEPO group underwent intraperitoneal injection of CEPO, while those in the CHF group received intraperitoneal injection of equivalent normal saline at the same time, those in the LY group received intraperitoneal injection of LY after model establishment, and those in the CEPO + LY group received the combined intraperitoneal injection of CEPO and LY simultaneously. Indicators for hemodynamics were determined using BL-410S bio-functional experiment system, including heart rate (HR), left ventricular end-diastolic pressure (LVEDP), left ventricular systolic pressure (LVSP) and maximal increased rate of left ventricular pressure (LVP)/maximal reduced rate of LVP (±dp/dtmax). Western blotting assay was utilized to determine the changes in activity of PI3-K/Akt signal pathway. LVSP and ±dp/dtmax in the CHF, the CEPO, the CEPO + LY and the LY groups were significantly lower than those in the control group (P<0.05); LVSP and ±dp/dtmax in the CEPO group were also elevated significantly compared with CHF, LY and CEPO + LY groups (P<0.05) with significant decreases in LVEDP and HR (P<0.05); compared with the CHF group, LVSP and ±dp/dtmax in the LY group were each significantly decreased (P<0.05), in the LY group, pAkt level was significantly lower than that in the CHF group (P<0.05). In conclusion, CEPO can generate the antagonist effect on CHF in rats through activation of PI3-K/Akt signal pathway.

Pathogenic substantiation of application of erythropoietin modified forms and peptide analogues as cytotprotectors

“…Тканезащитный эффект СЕРО продемонстрирован при терапии инфицированных ран, язвенных пролежней (рекуррентная ишемия-реперфузия) и перитонита [7]. Цитопротективный эффект СЕРО, связанный к активацией сигнального пути PI3-K/Akt, показан на модели хронической сердечной недостаточности у крыс, вызванной введением изопротеренола [39], и на модели ишемии-реперфузии почек у крыс [40]. Нейропротективный эффект СЕРО установлен на моделях нарушений обучения и памяти у крыс, вызванных интрагиппокампальным введением амилоидного пептида.…”

“…Как и Эпо, Epotris проникает через ГЭБ, ослабляет нейротоксические эффекты каината, однако не стимулирует эритропоэз. В литературе присутствует информация об исследованиях пептидного аналога Эпо Epopeptide-ab, представляющего собой последовательность из 17 аминокислот (AEHCSLNENITVPDTKV), соответствующую области AB-петли Эпо (последовательность аминокислот [30][31][32][33][34][35][36][37][38][39][40][41][42][43][44][45][46][47], который обладает активностью, сходной с целым белком. Нейропротективный эффект Epopeptide-ab подтвержден в опытах in vivo на модели ишемического повреждения нейронов [59].…”